Laparoscopy May Have Limited Role In Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

NEW YORK--Initial enthusiasm accompanying the introduction of laparoscopy in the diagnosis and treatment of prostate cancer has given way to a more realistic assessment of its value, R. Ernest Sosa, MD, said at a conference on prostate cancer at Lenox Hill Hospital. It continues to have value, but its role is limited and is unlikely to broaden.

NEW YORK--Initial enthusiasm accompanying the introduction oflaparoscopy in the diagnosis and treatment of prostate cancerhas given way to a more realistic assessment of its value, R.Ernest Sosa, MD, said at a conference on prostate cancer at LenoxHill Hospital. It continues to have value, but its role is limitedand is unlikely to broaden.

Dr. Sosa, associate professor of urology at Cornell UniversityMedical College, praised laparoscopy as a tool in staging as wellas dissection when lymph node metastases have been identified.He cautioned, however, that laparoscopy should be done only whenthere is a high likelihood of node involvement.

In selected patients, laparoscopy offers as advantages shorterhospital stay, lower costs (because of shorter stay), rapid convalescence,and reduced morbidity, compared with conventional surgery. Onthe down side, however, the procedure adds about 2 hours to surgicaltime and requires special expertise, making it a more expensiveoperation to perform.

The key to using laparoscopy effectively, Dr. Sosa said, liesin patient selection. Patients with T1a and T1b disease are notgood candidates because of the lower likelihood of positive nodes.In patients with later stage disease and high Gleason scales,the value of laparoscopy increases.

The complication rate has improved from 15% in 1991 to 6% today,and the time required to perform the procedure has been reduced,he noted.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Related Content